Skip to content

Author

E. Aydilek

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Allogeneic hematopoietic cell transplantation for therapy-related hematological malignancies in patients with multiple myeloma

Improved survival in multiple myeloma (MM) patients after high-dose chemotherapy, autologous hematopoietic cell transplantation (auto-HCT), and novel agents has led to an increasing incidence of therapy-related hematological malignancies (t-HM), although optimal management remains unclear, particularly the role of allo...

M. Maulhardt, A. Angleitner, J. Büntzel et al. · 0 citations
Open access Sep 2026

Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis.

Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients, while enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.

E. Shumilov, Lina J. Kolloch, Philipp Faustmann et al. · 0 citations
Open access Aug 2026

In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma.

In conclusion, axi-cel provided superior PFS and OS to patients with r/r LBCL compared with allo-HCT, primarily due to lower treatment-related mortality and improved disease control in patients with chemorefractory disease prior to cellular therapy.

M. Maulhardt, Lina J. Kolloch, G. Westhofen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.